- USDA Gets Tougher on Salmonella in Raw Breaded Chicken Products
- Fragments of Bird Flu Virus Found in 1 in 5 Milk Samples
- Clients Got HIV Through ‘Vampire Facial’ Microneedling Treatments
- Take the Stairs & Step Up to Longer Life
- ‘Drug Take Back Day’ is Saturday: Check for Leftover Opioids in Your Home
- Loneliness Can Shorten Lives of Cancer Survivors
- A Stolen Dog Feels Like Losing a Child, Study Finds
- Healthier Hearts in Middle Age Help Black Women’s Brains Stay Strong
- Better Scans Spot Hidden Inflammation in MS Patients
- Which Patients and Surgeries Are ‘High Risk’ for Seniors?
Zurampic Approved for Gout
Zurampic (lesinurad) has been approved by the U.S. Food and Drug Administration to control blood levels of uric acid associated with gout.
Gout, a form of arthritis, commonly emerges as pain, redness and swelling in the big toe. Uric acid normally is a natural waste product that’s passed through the kidneys. But when it builds up in the body, crystals may form and lead to gout.
Zurampic, approved in combination with a second drug called xanthine oxidase, helps the kidneys avoid reabsorbing uric acid, then aids the kidneys in excreting uric acid from the body, the FDA said in a news release.
Zurampic was evaluated in clinical studies involving more than 1,500 people. Those treated with the drug combination saw a drop in uric acid levels, compared to those who took placebos.
The most common side effects of Zurampic included headache, a rise in a blood compound called creatinine, flu and chronic heartburn (gastroesophageal reflux disease).
Zurampic’s label will include a boxed warning of the possibility of kidney failure if it is used without the second drug, or at higher-than-approved doses, the FDA said.
The agency said it ordered Zurampic’s Delaware-based manufacturer AstraZeneca to conduct additional trials to further evaluate the drug’s effects on the kidneys and heart.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.